Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements: the Randomized RAPID Trial

The RAPID trial is a randomized, single-center trial investigating whether giving atropine at heart rates below 60 beats per minute versus giving atropine only at heart rates below 30 beats per minute reduces the amount of norepinephrine needed to keep MAP above 65 mmHg in non-cardiac surgery patients with intraoperative bradycardia.

开始日期2025-04-07

申办/合作机构

University of Hamburg

100 项与硫酸阿托品相关的临床结果

登录后查看更多信息

100 项与硫酸阿托品相关的转化医学

登录后查看更多信息

100 项与硫酸阿托品相关的专利（医药）

登录后查看更多信息

35,289

项与硫酸阿托品相关的文献（医药）

2025-08-01·MICROBIAL PATHOGENESIS

Antiviral activity and mechanisms of action of atropine, rutin, and hypoxanthine against tomato Brown rugose fruit virus

Article

作者: Salehzadeh, Mehrdad ; Afsharifar, Alireza ; Izadpanah, Keramatollah

Plant viral diseases cause considerable damage to the agricultural industry and are difficult to control. Recently, botanical biopesticides that are environmentally friendly, safe for non-target organisms, and not prone to developing drug resistance have shown great potential as antiviral agents. In the present study a screening of natural products with antiviral potential was conducted, and three compounds - atropine, rutin, and hypoxanthine - were identified to possess anti-tomato brown rugose fruit virus (ToBRFV) activity. Further, the modes of action of these compounds were investigated. The results of the bioassay revealed that atropine, rutin and hypoxanthine were effective at concentrations of 50, 100 and 150 μg mL^-1 in inactivating, inhibiting proliferation and protecting against ToBRFV when combined with atropine and rutin. As the concentration of compounds increased, their antiviral properties were found to be enhanced. These compounds were found to reduce the expression of the coat protein and the replicase genes of ToBRFV. Atropine and rutin, in particular, demonstrated substantial anti-ToBRFV effects with diverse modes of action when used alone or in combination. Hypoxanthine demonstrated a comparatively weaker antiviral effect than the other two compounds, and when combined with the latter, the antiviral activity of the other compounds was also reduced to a certain extent. These results provided key proof that these compounds may represent a promising source of novel antiviral agents for agricultural use.

2025-07-01·Ophthalmology science

Additive Effect of Highly Aspherical Lenslet Target Spectacles to Children Inadequately Controlled by Atropine Monotherapy

Article

作者: Sim, Bryan Xiangrong ; Balakrishnan, Maithily ; Sri, Yudah ; Lam, Crystal Shue Wen ; Chan Poh Lin, Pauline ; Loh, Kai Lyn ; Htoon, Hla Myint ; Sim, Ralene Zi Hui ; Chia, Audrey Wei Lin

Purpose:

Myopia progression in children, especially in East Asia, is a significant public health concern. This study evaluated the efficacy of combining myopia control spectacle lenses with Highly Aspherical Lenslet Target (HALT) technology and atropine in children who continued to progress on low-dose atropine (LDA).

Design:

Prospective cohort.

Subjects:

Children aged 6-11 years with ≥0.5 diopters (D) myopia progression over 6 months on LDA (0.01% or 0.025%) were recruited.

Methods:

All participants used HALT (Essilor Stellest) spectacle lenses while maintaining their LDA dose. The changes in spherical equivalent (SE) and axial length (AL) were tracked for 6 months before and 6-12 months after starting combination treatment.

Main Outcome Measures:

Progression of SE and AL.

Results:

Fifty children (mean age 8.9 ± 1.1 years) were separated into group A (on 0.01% atropine daily, n20) and group B (on 0.01% atropine twice daily, n5 and 0.025% atropine nightly, n25). Most (86%) were ethnic Chinese. The baseline SE and AL showed no significant intergroup differences, with prior myopia progression (0.60D/0.24 mm) over 6 months. After adding HALT lenses, progression slowed to -0.06D/0.06 mm at 6 months and -0.15D/0.14 mm at 12 months. A hyperopic shift in AL was seen in 11 children (24%). However, the progression of >0.5D was noted in 20%, with 18% and 40% progressing by >0.3 mm and >0.15 mm, respectively. Univariate analysis suggested that children who progressed >0.10 mm over 6 months were more likely to be younger, whereas multivariate analysis suggested that change in AL was associated with smaller pupil size (possibly from poor compliance or absorption of atropine) at 6 months and younger age at 12 months, after controlling for sex, race, and baseline SE and AL. There were no complaints of glare, near, or peripheral blur in children after starting combination treatment.

Conclusions:

The addition of HALT spectacle lenses significantly reduced myopia progression in children, aged 6-11 years, who were poorly controlled on LDA alone demonstrating a potential synergistic effect with LDA. These findings supported combination therapy for managing challenging myopia cases.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

2025-07-01·EQUINE VETERINARY JOURNAL

Retrospective evaluation of the impact of atropine administration on incidence of post‐operative colic in healthy, isoflurane‐anaesthetised horses

Article

作者: Hogan, Patricia M. ; Dodam, John R. ; Curtiss, Alexandra L. ; Love, Kim ; Varner, Kelley M.

Abstract:

Background:

In anaesthetised horses, bradycardia secondary to high vagal tone can reduce cardiac output and blood pressure. The use of anticholinergics in horses is limited due to concerns about ileus and abdominal discomfort. This retrospective study sought to determine the prevalence of post‐operative abdominal discomfort in healthy horses that received atropine under isoflurane anaesthesia.

Study design:

A retrospective evaluation of 222 general anaesthesia events between January 2019 and December 2019 was undertaken.

Methods:

One hundred and eleven horses that received atropine were identified, and 111 case match controls that did not receive atropine were also selected. Information gathered from the medical records included signalment, anaesthetic drugs, surgical procedures, duration of anaesthesia and surgery, dobutamine and atropine administration, and the occurrence of abdominal discomfort for 24 h after anaesthesia. After initial data analysis, a second cohort of records was assessed separately. The horses in this group were castrated under general anaesthesia (with or without atropine; n = 68). Logistic regression models and Fisher's exact tests were used to look for factors contributing to abdominal discomfort post‐anaesthesia. The significance level was set to 5% (p < 0.05).

Results:

Atropine administration was not associated with the development of post‐anaesthetic abdominal discomfort (OR = 2.121, 95% CI [0.767, 5.869]; p = 0.2). Overall, 18/222 (8.1%) incidences of abdominal discomfort were identified. All incidents occurred in colts undergoing castration. In a separate analysis of only horses anaesthetised for castration, atropine was associated with developing abdominal discomfort (OR = 3.143, 95% CI [1.082, 9.132]; p = 0.04).

Discussion:

Atropine was not associated with post‐operative abdominal discomfort except in colts undergoing castration. All episodes of discomfort were mild and resolved with minimal intervention. The potential impact of insufficient analgesia in horses undergoing castration is a confounding factor and requires prospective investigation.

Conclusion:

Overall, atropine at a dose of 0.006 mg/kg IV appears to be a safe method to treat bradycardia in otherwise healthy horses anaesthetised for orthopaedic and upper airway procedures. Further work is required to determine if atropine is safe for colts undergoing castration.

422

项与硫酸阿托品相关的新闻（医药）

2025-06-13

·CPHI制药在线

首个国产贝伐珠单抗眼内制剂报产

关注并星标CPHI制药在线6月12日，兆科（广州）眼科药物有限公司（简称：兆科眼科）/东曜药业有限公司递交的贝伐珠单抗眼内注射溶液（研发代号：TAB014）的上市申请获CDE受理。这意味着国内首个贝伐珠单抗眼内注射溶液报产。TAB014是基于贝伐单抗的眼科制剂，以玻璃体注射的方式给药，其能够与VEGF特异性结合，并阻止其与受体结合，从而抑制血管生成。2017年，兆科广州与东曜药业签署协议，获得TAB014在中国（包括中国香港和中国澳门地区）的开发及商业化的特许权。2022年3月，兆科广州与东曜药业就TAB01签订补充协议书，据该补充协议，兆科眼科将成为TAB014在中国（包括中国香港和中国澳门地区）的整个产品生命周期的药品上市许可持有人（MAH），并将作为申请人向NMPA申请药品上市许可，所有临床前及临床研究数据仍将由兆科广州和东曜药业共同拥有。而东曜药业将继续负责TAB014的商业化生产。TAB014被开发用于治疗湿性年龄相关性黄斑病变（wAMD）、视网膜静脉阻塞（RVO）、脉络膜新生血管（CNV）以及其他眼部疾病。2025年1月，TAB014治疗wAMD的3期临床试验取得积极顶线结果：主要研究终点及关键次要终点均达到，非劣效于雷珠单抗。据此笔者推测此次TAB014申报的适应症为wAMD。年龄相关性黄斑变性（AMD）是造成老年人视力损害和不可逆失明的主要原因之一。据WHO报告，全球约有3000万AMD患者，每年约有50万人因为AMD而致盲。AMD致盲患者中，脉络膜新生血管（CNV）为特征的湿性年龄相关性黄斑变性（wAMD）比例高达90%。随着老年人口比例的不断上升，wAMD已经成为一个日益严重的社会医学问题，存在着巨大的未满足的临床需求。抗VEGF药物是wAMD的一线疗法。据悉全球已有5款抗VEGF药物被批准用于治疗wAMD等眼科疾病，其中除了法瑞西单抗是双靶点设计，其余均为单靶点VEGF药物。这几款药物中，阿柏西普最为畅销，2024年销售额高达95.45亿美元。法瑞西单抗凭借便捷的给药方式设计，上市后就显出重磅潜力，2024年销售额达43.78亿美元。已上市抗VEGF眼科药物（图片来源：华创证券）在国内，除了布西珠单抗，其余4款均已获批上市。据药智数据，2016-2024年我国医疗机构眼底用药中，康柏西普、雷珠单抗、阿柏西普3款抗VEGF生物药位列前三。其中本土药企康弘药业的康柏西普累计销售额超过100亿元，而且从2024年的数据来看，康柏西普在该年度的销售额已超过雷珠单抗，登顶眼底用药TOP1品种。此外，随着专利到期，齐鲁制药的阿柏西普类似物、雷珠单抗类似物已经获批。由于眼科专用抗VEGF药物定价不低，临床上常将静脉注射用贝伐珠单抗超适应症用于wAMD等眼科疾病患者。然而在实际操作过程中，往往存在制剂污染，质量不稳定等问题。除了TAB014，复宏汉霖也开发了贝伐珠单抗眼用制剂，即HLX04-O。HLX04-O是复宏汉霖在汉贝泰（HLX04，贝伐珠单抗生物类似药）的基础上保持活性成分不变，对处方、包装材料、规格和生产工艺等进行优化，开发的新的眼科制剂。2020年10月，亿胜生物与复宏汉霖达成全球许可协议，获得HLX04-O眼科适应症的共同开发权益。2025年4月，复宏汉霖宣布HLX04-O治疗wAMD中国患者的3期HLX04-O-wAMD-CN研究成功。结果显示，HLX04-O组第48周BCVA较基线改善的平均字母数变化结果非劣于雷珠单抗组，达到主要研究终点。而且，HLX04-O和雷珠单抗对wAMD患者人群整体、眼部、非眼部的安全性特征均相似，且安全性良好。据此研究结果，复宏汉霖计划携手亿胜生物在中国递交HLX04-O的新药上市申请（NDA）。值得一提的是，国外已批准了一款眼用贝伐珠单抗，即Lytenava（ONS-5010）。该药由Outlook Therapeutics开发，2024年5月在欧盟获批，用于治疗wAMD。不过该药在美国的上市之路并不顺利，其治疗wAMD的上市申请曾于2023年8月被FDA驳回。随后，Outlook Therapeutics应FDA要求，额外开展非劣效性III期研究以提供更多数据证明ONS-5010的疗效。遗憾的是，2024年11月，ONS-5010治疗wAMD的3期NORSE EIGHT研究未达到主要终点，相比对照组（雷珠单抗），ONS-5010在最佳矫正视力（BCVA）方面未达到非劣效性。然而，Outlook Therapeutics并未放弃ONS-5010。2025年4月，ONS-5010在美国重新递交的上市申请获FDA受理。据灼识行业咨询，预计2019年至2030年，中国湿性老年性黄斑部病变药物市场规模将从2.415亿美元增至约35亿美元，复合年增长率为27.5%。期待TAB014早日获批上市，从中分一杯羹。兆科眼科是一家致力于眼科药物研发、生产和销售的高新技术企业。除了TAB014，兆科眼科布局了丰富的眼科管线，适应症涉及糖尿病黄斑水肿、葡萄膜炎、干眼、近视等。2025年以来，除了TAB014，兆科眼科还有2个眼科新药申请上市：2025年5月，环孢素眼用凝胶（前称：环孢素A眼凝胶）治疗干眼症的上市申请获CDE受理，相关受理号为CXHS2500052。值得一提的是，兆科眼科的环孢素眼用凝胶是专利水凝胶，而此创新提升了环孢素于眼表的药物代谢动力学效能及曝露量，给予环孢素更多时间抑制干眼症。已公布的2期研究结果显示：0.05%环孢素眼用凝胶（每日晚间一次）的疗效及安全特性至少与Restasis?（0.05%环孢素，每日两次）者类近，可有效消除日间给药的需要以及相关的不适和不便。此外，3期研究（COSMO）结果显示环孢素眼用凝胶最早可于两星期起效。2025年1月，NVK002（0.01%低浓度阿托品）用于延缓儿童近视加深的上市申请获CDE受理。据悉，NVK002是Nevakar开发的一款具有专利配方、不含防腐剂、每日1次的低浓度阿托品滴眼液，适用于3-17岁近视患者。2020年10月，兆科眼科获得NVK002科在中国、韩国和东南亚地区的开发和商业化权益。2024年3月，国内首款延缓儿童近视进展低浓度硫酸阿托品滴眼液SQ-729获批。若顺利，兆科眼科的NVK002有望成为国内第二款获批上市的近视眼药水。END【企业推荐】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

临床3期专利到期上市批准申请上市

2025-06-12

·Business Wire

HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting

SALT LAKE CITY--(BUSINESS WIRE)--HOYA Vision Care (https://www.hoyavision.com/) today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company’s 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world’s longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said "This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children’s vision health for the future.” The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4 "Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child." said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3 “With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,” said Dr. Vlasak. “With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.” For the abstracts presented at ARVO 2025, please visit https://www.hoyavision.com/visionary-knowlegde/blogs-and-article/conference-arvo-2025/ Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.

临床结果

2025-06-10

·赛柏蓝

24家药企股价翻倍（附名单）

编者按：本文来自药智网，作者杨柳儿；赛柏蓝授权转载，编辑凯西今年以来，医药板块一改前几年“寒冬”景象，在众多板块中脱颖而出，涨幅傲视群雄。截至6月3日，今年A股和H股医药板块上涨明显，约70%企业股价上涨，多家药企股价实现翻倍增长。据药智网统计和铂医药、舒泰神、加科思、荣昌生物、三生制药、一品红等24家公司股价在今年实现翻倍式上涨。其中德琪医药股价上涨5倍多，成为今年医药行业的“涨幅冠军”。其股价上涨主要得益于核心产品塞利尼索（Selinexor）在亚太市场的商业化成功以及Claudin 18.2 ADC和其他在研候选分子的跨国BD预期。表1 2025.01.02-2025.06.03区间涨幅超过100%的药企注.不包括药品分销、医疗器械公司，以及市值小于10亿元的小盘股‌；数据来源：i问财网站、根据公开资料整理01BD交易成股价催化剂近期，三生制药宣布与辉瑞签署协议，授予后者PD-1/VEGF双抗SSGJ-707的全球权益（不含中国）。这笔交易的潜在总金额超60亿美元，其中首付款达到12.5亿美元，创下中国创新药license-out首付款纪录。这一消息直接刺激三生制药和三生国健股价大幅上涨。BD交易不仅带来现金流，更是跨国药企对中国创新药研发质量的背书，BD交易因此也成为药企股价的重要催化剂。和铂医药、百奥赛图等平台型公司在达成多项BD交易后，得到了市场的认可，估值大幅上涨。映恩生物今年4月登陆港交所，发行价94.6港元，首日飙升116.7%，投资者的热情很大一部分也来源于映恩生物此前已达成了多笔大额BD交易，在没有商业化产品的情况下就实现了自主造血。02研发突破推动价值重塑当然，大部分公司推动股价上涨的主要驱动力还是核心管线的推进。舒泰神的凝血因子X激活剂STSP-0601的IIb期临床试验取得重大突破，12小时止血率高达81.94%（P<0.0001），意味着该产品在治疗伴抑制物血友病方面效果显著。加思科首款产品KRAS G12C抑制剂戈来雷塞获批上市，用于KRAS G12C突变的非小细胞肺癌（NSCLC）二线及以上治疗，销售峰值预计将达20亿元。荣昌生物自免药物泰它西普国内成功拿下全身型重症肌无力（gMG）这一重磅适应症，而且还有很强的出海预期。一品红痛风新药URAT1抑制剂AR882在美国进入3期临床研究，在同类药物中进度靠前，很有可能在全球痛风市场占得重要一席之地。科兴制药白蛋白紫杉醇在欧盟、英国获批上市，在研产品多个具备BIC、FIC潜力。兆科眼科拥有NVK002、环孢素A眼凝胶、TAB014三大眼科管线，有望在眼科这一特色赛道打开增长空间。康宁杰瑞的HER2双特异性抗体KN026联合化疗在治疗HER2阳性胃癌的Ⅱ/Ⅲ期临床研究中取得积极结果，显著改善了患者的PFS，并具有OS（总生存期）获益趋势。益方生物的新型口服TYK2选择性抑制剂D-2570具备全球BIC潜力，拟用于治疗银屑病等自身免疫性疾病。科济药业实体瘤CAR-T细胞产品舒瑞基奥仑赛注射液在中国用于治疗晚期GC/GEJ的确证性Ⅱ期试验（CT041-ST-01，NCT04581473）已完成患者入组工作并已达成试验主要终点，即将提交上市申请。诺思兰德核心产品NL003（塞多明基注射液）已提交NDA，并完成全流程技术审评，预计将在近期获批上市。如果成功上市，将成为国内首个裸质粒型基因治疗药物，并有望成为10亿元以上大单品。另外，还有部分公司在经历低谷后，重新出发，在新赛道赢得机遇。歌礼制药将管线重心转移到代谢领域，开发了小分子GLP-1R激动剂ASC30。永安药业在牛磺酸大涨的浪潮下，开拓饮料、宠物食品新战线。热景生物从IVD行业跨界做创新药，参股的舜景医药、智源生物都已有新药项目进入临床阶段。03结语随着科创板第五套上市标准重启，政策明确支持未盈利科技企业上市，创新药行业正迎来新一轮发展机遇。但投资者也需清醒认识到创新药行业的高风险性。多数创新药企业仍处于未盈利状态，未来管线的进展将大幅影响其股价的涨跌。END内容沟通：郑瑶（13810174402）

引进/卖出抗体药物偶联物临床2期上市批准临床3期

100 项与硫酸阿托品相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02069	硫酸阿托品	A03BA01 S01FA01	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
近视	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	2021-09-13
心脏停搏	美国	Accord Healthcare, Inc.	2020-09-29
蘑菇中毒	美国	Accord Healthcare, Inc.	2020-09-29
心动过缓	美国	Fresenius Kabi USA LLC	2018-01-26
弱视	美国	Rising Pharmaceuticals, Inc.	2014-07-18
心律失常	中国	成都第一制药有限公司	1981-01-01
疼痛	中国	成都第一制药有限公司	1981-01-01
中毒	中国	成都第一制药有限公司	1981-01-01
有机磷中毒	美国	Meridian Medical Technologies LLC	1973-05-15
眼肌麻痹	日本	Santen Pharmaceutical Co., Ltd.	1970-03-31
睫状肌麻痹	日本	ROHTO NITTEN Co., Ltd.	1968-07-20
瞳孔散大	日本	ROHTO NITTEN Co., Ltd.	1968-07-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
变性近视	临床3期	美国	欧康维视生物医药（上海）有限公司	2021-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06366087 (SABER, CTgov)	临床1期	-	46	Atropine Sulfate Ophthalmic Solution USP, 1% (Sublingual)	壓憲蓋餘獵鹽願鹽襯築(廠築範鏇鬱窪選夢憲製) = 襯範鏇獵鑰齋襯廠窪糧廠鹹遞襯網鹽網襯範廠 (齋壓廠廠餘鹽廠齋願蓋, 23.0) 更多	-	2025-04-04
				Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL) (Intramuscular)	壓憲蓋餘獵鹽願鹽襯築(廠築範鏇鬱窪選夢憲製) = 獵醖窪鹽餘構鑰膚襯齋廠鹹遞襯網鹽網襯範廠 (齋壓廠廠餘鹽廠齋願蓋, 19.0) 更多
NCT06209281 (Mini-CHAMP, NEWS) 人工标引	临床3期	近视	526	NVK002	窪膚糧襯糧網顧膚繭襯(廠製顧遞鏇鑰醖獵製醖) = 达到了其主要疗效终点。齋網觸鹽鏇鏇獵齋醖獵 (鏇醖簾鑰糧顧蓋蓋鏇網 ) 达到更多	积极	2025-01-07
				Placebo
NCT03750656 (HyTa Stent, CTgov)	临床4期	下尿路症状	5	Hyoscyamine (Hyoscyamine)	繭構鏇選餘醖網夢鹽餘(簾醖壓範憲鑰齋選選餘) = 鏇齋網齋衊窪衊蓋觸觸遞廠鹹積夢餘遞襯襯壓 (鑰簾窪膚淵網繭窪範蓋, 鏇醖窪積鹹鹹糧觸衊選 ~ 糧鏇衊鹹積選糧製鏇構) 更多	-	2024-12-03
				Tamsulosin (Tamsulosin)	繭構鏇選餘醖網夢鹽餘(簾醖壓範憲鑰齋選選餘) = 鏇製蓋簾範鬱繭製願襯遞廠鹹積夢餘遞襯襯壓 (鑰簾窪膚淵網繭窪範蓋, 鹽遞鏇鏇範簾廠願遞醖 ~ 鹽遞遞鹹簾壓壓壓淵製) 更多
NCT03350620 (CHAMP, CTgov)	临床3期	近视	670	NVK-002 Concentration 1 (NVK-002 Concentration 1)	夢願鹽憲構構繭夢鏇壓 = 鑰積鬱繭艱積憲壓簾網壓網觸蓋憲鏇鬱蓋憲願 (夢餘製壓範選醖獵網膚, 憲廠淵壓選鏇膚繭餘淵 ~ 壓憲壓夢蓋淵遞衊築願) 更多	-	2024-11-27
				NVK-002 Concentration 2 (NVK-002 Concentration 2)	夢願鹽憲構構繭夢鏇壓 = 膚夢構襯蓋鹽廠繭製憲壓網觸蓋憲鏇鬱蓋憲願 (夢餘製壓範選醖獵網膚, 淵遞鹽鹽願願鏇鹹繭廠 ~ 壓網蓋築鏇網襯齋淵廠) 更多
NCT06209320 (China CHAMP, Corporate Publications \| NEWS) 人工标引	临床3期	近视	-	NVK002	餘淵鏇鹽鏇範壓憲獵繭(製蓋鏇艱鏇鏇糧餘願艱) = NVK002滴眼液组（0.01%和0.02%剂量）对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，且具有剂量依赖。鑰醖繭醖築選網艱觸鹽 (憲獵餘齋窪壓窪鬱襯鬱 ) 更多	积极	2024-10-24
				Placebo
NCT03374306 (CTgov)	N/A	近视	71	Atropine (0.01%) (Atropine 0.01%)	蓋鹽膚選築艱窪鹹餘鬱(製膚憲鑰顧顧簾襯鏇壓) = 淵顧積醖襯願遞網鏇淵範願鑰觸鑰廠憲獵獵願 (構壓餘餘廠製壓網構醖, 0.39) 更多	-	2024-10-16
				Artificial tear (Artifical Tear)	蓋鹽膚選築艱窪鹹餘鬱(製膚憲鑰顧顧簾襯鏇壓) = 襯壓壓願願顧遞廠鹽顧範願鑰觸鑰廠憲獵獵願 (構壓餘餘廠製壓網構醖, 0.41) 更多
EURETINA2024 人工标引	N/A	近视	97	0.01% Atropine Eye Drops	艱繭網衊醖艱憲製製蓋(積夢網繭餘繭選衊憲夢) = 憲艱齋範範顧襯鏇願範遞觸繭齋襯衊襯鹽構膚 (鹽製積積願鑰構鹽憲鬱, 0.01 ~ 0.19) 更多	积极	2024-09-19
				0.1% LAtropineose Atropine Eye Drops	艱繭網衊醖艱憲製製蓋(積夢網繭餘繭選衊憲夢) = 簾積繭範艱鏇夢鹹窪蓋遞觸繭齋襯衊襯鹽構膚 (鹽製積積願鑰構鹽憲鬱, -0.01 ~ 0.17) 更多
NCT03699423 (Pubmed \| J Ocul Pharmacol Ther) 人工标引	临床1期	近视	57	0.01% atropine eye drops	膚壓願壓襯網鹽憲範鏇(鑰餘衊壓齋蓋膚醖築鬱) = 製鏇餘築鏇繭遞廠夢齋鏇遞衊鑰齋選膚觸繭膚 (築網顧齋糧餘獵廠遞淵 ) 更多	积极	2024-04-15
				0.02% atropine eye drops	膚壓願壓襯網鹽憲範鏇(鑰餘衊壓齋蓋膚醖築鬱) = 窪簾衊積壓範顧襯膚顧鏇遞衊鑰齋選膚觸繭膚 (築網顧齋糧餘獵廠遞淵 ) 更多
APAO2024	N/A	-	-	Low-dose atropine eyedrops	鏇鑰顧鑰憲鬱顧糧壓鹽(衊餘蓋製鬱壓範糧築蓋) = 鑰鑰廠窪願膚壓鏇襯窪夢網網獵選顧醖觸範襯 (簾襯積觸範構鏇餘夢餘, 0.32) 更多	-	2024-02-22
APAO2024	N/A	近视	-	Atropine 0.01%	鏇鹽蓋夢憲憲選簾廠醖(糧遞蓋夢積餘醖醖鬱艱) = 觸蓋鏇製遞窪窪夢願窪願蓋鑰鏇鑰憲獵範網壓 (壓鬱糧選憲製鬱襯鏇淵 ) 更多	-	2024-02-22